Ovid Therapeutics Inc. OVID 深 滬
等待開盤 07-18 09:30:00 美东时间
0.4793
+0.089
+22.90%
華盛通- 最 高0.61
- 今 開0.42
- 成交量 2451.27万股
- 最 低 0.41
- 昨 收 0.39
- 總市值 3408.28万
- 52周最高 1.47
- 市盈率 靜 --
- 換手率 34.47%
- 52周最低 0.2425
- 委 比 -93.10%
- 總股本 7110.95万
- 歷史最高 15.89
- 量 比 39.80
- 振 幅 51.28%
- 歷史最低 0.2425
- 每 手 1
- 風險率 0.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多WESTERN COPPER AND GOLD PROVIDES UPDATE ON ESE SUBMISSION
VANCOUVER, BC, July 15, 2025 /PRNewswire/ - Western Copper and Gold Corporation ("Western" or the "Company") (TSX: WRN) (NYSE American: WRN) is pleased to provide an update on its Environmen...
07-15 19:30
GALIANO GOLD PROVIDES NOTICE OF SECOND QUARTER 2025 RESULTS
VANCOUVER, BC, July 8, 2025 /PRNewswire/ - Galiano Gold Inc. ("Galiano" or the "Company") (TSX: GAU) (NYSE American: GAU) is pleased to announce it will release its second quarter ("Q2") 202...
07-08 20:30
Ovid Therapeutics Sells Ganaxolone Royalties to Immedica
Ovid Therapeutics ( ($OVID) ) has provided an announcement. On June 23, 2025, O...
06-25 20:49
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
Ovid Therapeutics sold its future royalties for ganaxolone outside of China to Immedica Pharma for $7 million. This non-dilutive funding supports Ovid's operations, while Immedica gains control of additional ganaxolone IP rights. Immedica will assume costs related to the licensed IP and expand the license to include more indications. The deal does not affect Ovid's current pipeline.
06-25 12:00
BIRKS GROUP PROVIDES A CORPORATE UPDATE
MONTREAL, June 9, 2025 /CNW/ - Birks Group Inc. (the "Company", "Birks Group" or "we") (NYSE American LLC: BGI) is pleased to provide an update on its corporate activities. All figures prese...
06-09 19:30
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
Ovid Therapeutics will host an event on June 12, 2025, to discuss the use of biomarkers in epilepsy drug development, focusing on OV329, a next-generation GABA-AT inhibitor. Dr. Alexander Rotenberg, a leading epileptologist, will join Ovid management to explore how advanced imaging tools and biomarkers drive evidence-based approaches in drug development. OV329 aims to reduce seizures by optimally delivering GABA, offering a novel treatment for tr...
06-05 11:30
美股大行评级 | 潜在涨幅1562.13%！Cingulate获Ascendiant Capital升目标价至61美元，维持"买入"评级
潜在涨幅1562.13%！Cingulate获Ascendiant Capital升目标价至61美元，维持"买入"评级
05-28 09:04
HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Lowers Price Target to $1.5
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and lowers the price target from $2 to $1.5.
05-27 19:01
Ovid Therapeutics Analyst Ratings
Unity Software(U.US) reported fourth-quarter financial results after the market...
05-27 18:54
LIONSGATE REPORTS RESULTS FOR FOURTH QUARTER FISCAL 2025
Revenue was $1.1 Billion, up 22% Year Over Year Net Income Attributable to Shareholders was $21.9 Million or $0.10 Diluted Earnings Per Share Adjusted Net Income Attributable to Shareholders...
05-23 04:05
